Brain scans reveal how Weight-Loss drug targets appetite
NCT ID NCT02400359
First seen May 04, 2026 · Last updated Jun 22, 2026 · Updated 7 times
Summary
This study uses brain scans (fMRI) to see how the weight-loss drug lorcaserin changes activity in brain areas that control appetite and food intake. Forty obese adults will receive either lorcaserin or a placebo pill. Researchers will also measure changes in body composition. The goal is to understand the brain mechanisms behind the drug's effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lorcaserin (Belviq)
What this could lead to
If successful, this could clarify how lorcaserin works in the brain to reduce appetite, potentially improving weight-loss treatments.
What could go wrong
This is a small, early-phase study focused on brain imaging, not weight loss itself. Results may not translate to real-world weight reduction or long-term safety.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.